Back to Search Start Over

Second relapse of pediatric patients with acute myeloid leukemia: a report on current treatment strategies and outcome of the AML-BFM study group

Authors :
Rasche, Mareike
Steidel, Emma
Zimmermann, Martin
Bourquin, Jean-Pierre
Boztug, Heidrun
Janotova, Iveta
Kolb, E. Anders
Lehrnbecher, Thomas
Neuhoff, Nils von
Niktoreh, Naghmeh
Mühlegger, Nora
Sramkova, Lucie
Stary, Jan
Walter, Christiane
Creutzig, Ursula
Dworzak, Michael
Reinhardt, Dirk
Rasche, Mareike
Steidel, Emma
Zimmermann, Martin
Bourquin, Jean-Pierre
Boztug, Heidrun
Janotova, Iveta
Kolb, E. Anders
Lehrnbecher, Thomas
Neuhoff, Nils von
Niktoreh, Naghmeh
Mühlegger, Nora
Sramkova, Lucie
Stary, Jan
Walter, Christiane
Creutzig, Ursula
Dworzak, Michael
Reinhardt, Dirk
Publication Year :
2021

Abstract

Simple Summary: Children with acute myeloid leukemia (AML) experience high relapse rates of about 30%; still, survival rates following the first relapse are encouraging. Hence, it is critically important to examine the consequences of a second relapse; however, little is known about this subgroup of patients. This retrospective population-based analysis intends to describe response, survival and prognostic factors relevant for the survival of children with second relapse of AML. Treatment approaches include many different therapeutic regimens, including palliation and intensive treatment with curative intent (63% of the patients). Survival is poor; however, patients who respond to reinduction attempts can be rescued with subsequent hematopoietic stem cell transplantation. We deciphered risk factors, such as short time interval from first to second relapse below one year as being associated with a poor outcome. This analysis will help to improve future international treatment planning and patient care of children with advanced AML. Abstract: Successful management of relapse is critical to improve outcomes of children with acute myeloid leukemia (AML). We evaluated response, survival and prognostic factors after a second relapse of AML. Among 1222 pediatric patients of the population-based AML-Berlin–Frankfurt–Munster (BFM) study group (2004 until 2017), 73 patients met the quality parameters for inclusion in this study. Central review of source documentation warranted the accuracy of reported data. Treatment approaches included palliation in 17 patients (23%), intensive therapy with curative intent (n = 46, 63%) and other regimens (n = 10). Twenty-five patients (35%) received hematopoietic stem cell transplantation (HSCT), 21 of whom (88%) had a prior HSCT. Survival was poor, with a five-year probability of overall survival (pOS) of 15 ± 4% and 31 ± 9% following HSCT (n = 25). Early second relapse (within one year after first relapse) was associated with dismal outco

Details

Database :
OAIster
Notes :
application/octet-stream, English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1362825602
Document Type :
Electronic Resource